Kathleen Pratt Laboratory

The Pratt laboratory studies the bleeding disorder known as hemophilia A. Hemophilia A results from a defect in the gene for factor VIII, which is an important clotting factor in blood. Treatment consists of infusions with factor VIII protein in order to correct the bleeding disorder. Approximately 25 percent of the patients, however, develop an immune response to the infused factor VIII, and the neutralizing antibodies (commonly called "inhibitors") can result in bleeding that is difficult to control. We are interested in developing new therapies to help prevent and/or treat patients who develop factor VIII inhibitors.

Areas of Study

• Role of factor VIII in blood clotting
• Mechanisms of immune responses to factor VIII
• New versions of factor VIII that will be less likely to spark immune responses
• Read more

Dr. Pratt's Background

• Joined the Blood Center in 2005
• Assistant Professor of Medicine, Division of Hematology, University of Washington School of Medicine
• Previously Staff Scientist at Fred Hutchinson Cancer Research Center
• Previously Postdoctoral Fellow, Earl Davie laboratory, University of Washington

Kathleen Pratt, PhD
Assistant Member
Puget Sound Blood Center
Research Institute

Acting Assistant Professor of
Medicine Division of Hematology
University of Washington
School of Medicine

Puget Sound Blood Center
Research Institute
1551 Eastlake Avenue E.
Seattle, WA 98102

Email: kathleenp@psbc.org
Phone: (206) 568-2232
Fax: (206) 587-6056

Rachel A. Sessum
Administrative Specialist
Email: rachels@psbc.org
Phone: (206) 568-2246
Fax: (206) 587-6056